We are live on ! Find out more

20 hedge funds and large institutions have $2.03M invested in PAVmed in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 9 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.03% more ownership

Funds ownership: 0.31%0.35% (+0.03%)

13% less funds holding

Funds holding: 2320 (-3)

35% less capital invested

Capital invested by funds: $3.12M → $2.03M (-$1.08M)

50% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 6

78% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 9

Holders
20
Holders Change
-3
Holders Change %
-13.04%
% of All Funds
0.29%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
2
Reduced
9
Closed
6
Calls
$4K
Puts
Net Calls
+$4K
Net Calls Change
-$375K
Name Holding Trade Value Shares
Change
Change in
Stake
Simplex Trading
26
Simplex Trading
Illinois
-$1.51K -20 -61%
RIM
27
Rockbridge Investment Management
New York
-$112 -1 Closed
Royal Bank of Canada
28
Royal Bank of Canada
Ontario, Canada
-$76 -1 Closed
Fidelity Investments
29
Fidelity Investments
Massachusetts
-$4

PAVM Hedge Fund Activity: Q1 2024 in Review

20 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in PAVmed (PAVM) for Q1 2024, worth a combined $2.03M — down 35% from $3.12M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of PAVM and 3 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 2 added.

The largest buyer was First Manhattan, adding an estimated $567K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $93K sold.

  • 20 institutional investors held PAVmed (PAVM) as of Q1 2024, down from 23 in Q4 2023.
  • Funds reported $2.03M of PAVmed stock for Q1 2024, down 35% quarter-over-quarter.
  • 3 funds opened new PAVmed positions in Q1 2024 and 6 closed out, a net change of -3 holders.
  • The largest PAVmed buyer in Q1 2024 was First Manhattan, an estimated $567K added.
  • The largest PAVmed seller in Q1 2024 was Susquehanna International Group, an estimated $93K sold.

Based on aggregated 13F filings for Q1 2024.